This site has twice noted that the CagriSema trials compared the combination against placebo while leaving the question a buyer actually has unanswered: does adding cagrilintide beat semaglutide by itself. That comparison has now been run [1]. The placebo-controlled version is covered on this site’s sister publication.
Over 68 weeks, weight fell 18.4% on the combination and 11.9% on semaglutide alone, a difference of 6.5 percentage points with a confidence interval from -8.4 to -4.6. Both arms escalated to 2.4 mg, so this is not a mismatched-dose comparison of the kind this site keeps finding elsewhere — the problem set out in the tirzepatide network comparison.
The population is the limit on reading the absolute numbers across. Participants were from east Asia, and the authors frame their conclusion that way. The semaglutide-alone arm reached -11.9%, noticeably below the figures from the Western trials in the pooled weight-loss averages, which means the starting population and the response differ. The 6.5-point gap between arms is the trial’s finding; the -18.4% is not a number to promise anyone elsewhere.
Two details are worth noting for anyone weighing the evidence. The trial was 68% male, which is unusual for an obesity trial and the reverse of most, and it was funded by Novo Nordisk, which is stated in the paper and ordinary for a phase 3 program. Discontinuation ran 10% against 6%, slightly higher on the combination — modest beside the class-wide figures in the network meta-analysis of nineteen drugs.
Where this leaves a reader is that combination therapy has now cleared the bar it previously avoided — at least for this pairing, in this population. That sits against the result in the zalfermin trial, where every combination failed and the single agent won, and suggests that whether stacking helps depends entirely on which second drug and which outcome.